VYVANSE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7659253 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7662787 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(1 year, 2 months ago) | |
| US7655630 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7723305 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7674774 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7678771 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7678770 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7662788 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7718619 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7671031 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7687467 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7713936 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7671030 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7659254 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7105486 | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Feb, 2023
(1 year, 2 months ago) | |
| US7687466 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
| US7223735 | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Feb, 2023
(1 year, 2 months ago) | |
| US7700561 | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Feb, 2023
(1 year, 2 months ago) | |
|
US7655630 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7662788 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7700561 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7723305 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7671030 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7718619 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7674774 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7678770 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7678771 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7105486 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine compounds |
Aug, 2023
(8 months ago) | |
|
US7223735 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(8 months ago) | |
|
US7659253 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7659254 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7662787 (Pediatric) | TAKEDA PHARMS USA | Abuse resistant lysine amphetamine compounds |
Aug, 2023
(8 months ago) | |
|
US7671031 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7713936 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7687466 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
|
US7687467 (Pediatric) | TAKEDA PHARMS USA | Abuse-resistant amphetamine prodrugs |
Aug, 2023
(8 months ago) | |
Vyvanse is owned by Takeda Pharms Usa.
Vyvanse contains Lisdexamfetamine Dimesylate.
Vyvanse has a total of 36 drug patents out of which 36 drug patents have expired.
Expired drug patents of Vyvanse are:
- US7723305
- US7674774
- US7678771
- US7678770
- US7662788
- US7718619
- US7671031
- US7687467
- US7713936
- US7671030
- US7659254
- US7105486
- US7687466
- US7223735
- US7700561
- US7655630*PED
- US7662788*PED
- US7700561*PED
- US7723305*PED
- US7671030*PED
- US7718619*PED
- US7674774*PED
- US7678770*PED
- US7678771*PED
- US7105486*PED
- US7223735*PED
- US7659253*PED
- US7659254*PED
- US7662787*PED
- US7671031*PED
- US7713936*PED
- US7687466*PED
- US7687467*PED
- US7659253
- US7662787
- US7655630
Vyvanse was authorised for market use on 30 October, 2014.
Vyvanse is available in capsule;oral dosage forms.
Vyvanse can be used as treatment of attention deficit hyperactivity disorder (adhd) in adults, indicated for the treatment of attention-deficit/hyperactivity disorder (adhd), for the treatment of attention deficit hyperactivity disorder (adhd).
Drug patent challenges can be filed against Vyvanse from 23 February, 2011.
The generics of Vyvanse are possible to be released after 24 August, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-703) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Feb 23, 2012 |
| New Indication(I-645) | Jan 31, 2015 |
| M(M-188) | Oct 14, 2019 |
| New Patient Population(NPP) | Nov 10, 2013 |
| M(M-82) | Apr 05, 2013 |
Drugs and Companies using
LISDEXAMFETAMINE DIMESYLATE ingredient
NCE-1 date:
Market Authorisation Date:
30 October, 2014Treatment:
Indicated for the treatment of attention-deficit/hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd); Treatment of attention deficit hyperactivity disor...Dosage:
How can I launch a generic of VYVANSE before its drug patent expiration?
More Information on Dosage
VYVANSE family patents
